nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000656	0.000656	CcSEcCtD
Paricalcitol—Diarrhoea—Captopril—systemic scleroderma	0.000656	0.000656	CcSEcCtD
Paricalcitol—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000655	0.000655	CcSEcCtD
Paricalcitol—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000655	0.000655	CcSEcCtD
Paricalcitol—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000654	0.000654	CcSEcCtD
Paricalcitol—Erectile dysfunction—Prednisone—systemic scleroderma	0.000653	0.000653	CcSEcCtD
Paricalcitol—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000652	0.000652	CcSEcCtD
Paricalcitol—Feeling abnormal—Leflunomide—systemic scleroderma	0.000651	0.000651	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000651	0.000651	CcSEcCtD
Paricalcitol—Fatigue—Mycophenolic acid—systemic scleroderma	0.00065	0.00065	CcSEcCtD
Paricalcitol—Nausea—Mometasone—systemic scleroderma	0.000648	0.000648	CcSEcCtD
Paricalcitol—Anorexia—Lisinopril—systemic scleroderma	0.000647	0.000647	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000646	0.000646	CcSEcCtD
Paricalcitol—Constipation—Mycophenolic acid—systemic scleroderma	0.000645	0.000645	CcSEcCtD
Paricalcitol—Pain—Mycophenolic acid—systemic scleroderma	0.000645	0.000645	CcSEcCtD
Paricalcitol—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000644	0.000644	CcSEcCtD
Paricalcitol—Weight decreased—Prednisone—systemic scleroderma	0.000642	0.000642	CcSEcCtD
Paricalcitol—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000641	0.000641	CcSEcCtD
Paricalcitol—Cough—Mycophenolate mofetil—systemic scleroderma	0.000636	0.000636	CcSEcCtD
Paricalcitol—Hypotension—Lisinopril—systemic scleroderma	0.000634	0.000634	CcSEcCtD
Paricalcitol—Dizziness—Captopril—systemic scleroderma	0.000634	0.000634	CcSEcCtD
Paricalcitol—Depression—Prednisone—systemic scleroderma	0.00063	0.00063	CcSEcCtD
Paricalcitol—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000629	0.000629	CcSEcCtD
Paricalcitol—Urticaria—Leflunomide—systemic scleroderma	0.000628	0.000628	CcSEcCtD
Paricalcitol—Abdominal pain—Leflunomide—systemic scleroderma	0.000625	0.000625	CcSEcCtD
Paricalcitol—Body temperature increased—Leflunomide—systemic scleroderma	0.000625	0.000625	CcSEcCtD
Paricalcitol—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000621	0.000621	CcSEcCtD
Paricalcitol—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000621	0.000621	CcSEcCtD
Paricalcitol—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000621	0.000621	CcSEcCtD
Paricalcitol—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000621	0.000621	CcSEcCtD
Paricalcitol—Breast disorder—Methotrexate—systemic scleroderma	0.00062	0.00062	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000619	0.000619	CcSEcCtD
Paricalcitol—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000618	0.000618	CcSEcCtD
Paricalcitol—Hypersensitivity—Azathioprine—systemic scleroderma	0.000616	0.000616	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000616	0.000616	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000616	0.000616	CcSEcCtD
Paricalcitol—Insomnia—Lisinopril—systemic scleroderma	0.000614	0.000614	CcSEcCtD
Paricalcitol—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000613	0.000613	CcSEcCtD
Paricalcitol—Paraesthesia—Lisinopril—systemic scleroderma	0.00061	0.00061	CcSEcCtD
Paricalcitol—Vomiting—Captopril—systemic scleroderma	0.00061	0.00061	CcSEcCtD
Paricalcitol—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000607	0.000607	CcSEcCtD
Paricalcitol—Dyspnoea—Lisinopril—systemic scleroderma	0.000605	0.000605	CcSEcCtD
Paricalcitol—Rash—Captopril—systemic scleroderma	0.000604	0.000604	CcSEcCtD
Paricalcitol—Dermatitis—Captopril—systemic scleroderma	0.000604	0.000604	CcSEcCtD
Paricalcitol—Somnolence—Lisinopril—systemic scleroderma	0.000604	0.000604	CcSEcCtD
Paricalcitol—Headache—Captopril—systemic scleroderma	0.000601	0.000601	CcSEcCtD
Paricalcitol—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.0006	0.0006	CcSEcCtD
Paricalcitol—Dyspepsia—Lisinopril—systemic scleroderma	0.000598	0.000598	CcSEcCtD
Paricalcitol—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000596	0.000596	CcSEcCtD
Paricalcitol—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000596	0.000596	CcSEcCtD
Paricalcitol—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000595	0.000595	CcSEcCtD
Paricalcitol—Asthma—Methotrexate—systemic scleroderma	0.000593	0.000593	CcSEcCtD
Paricalcitol—Infection—Mycophenolate mofetil—systemic scleroderma	0.000591	0.000591	CcSEcCtD
Paricalcitol—Decreased appetite—Lisinopril—systemic scleroderma	0.00059	0.00059	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000586	0.000586	CcSEcCtD
Paricalcitol—Fatigue—Lisinopril—systemic scleroderma	0.000585	0.000585	CcSEcCtD
Paricalcitol—Shock—Mycophenolate mofetil—systemic scleroderma	0.000585	0.000585	CcSEcCtD
Paricalcitol—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000583	0.000583	CcSEcCtD
Paricalcitol—Hypersensitivity—Leflunomide—systemic scleroderma	0.000582	0.000582	CcSEcCtD
Paricalcitol—Pancreatitis—Methotrexate—systemic scleroderma	0.000581	0.000581	CcSEcCtD
Paricalcitol—Pain—Lisinopril—systemic scleroderma	0.000581	0.000581	CcSEcCtD
Paricalcitol—Constipation—Lisinopril—systemic scleroderma	0.000581	0.000581	CcSEcCtD
Paricalcitol—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000578	0.000578	CcSEcCtD
Paricalcitol—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000575	0.000575	CcSEcCtD
Paricalcitol—Diarrhoea—Azathioprine—systemic scleroderma	0.000572	0.000572	CcSEcCtD
Paricalcitol—Nausea—Captopril—systemic scleroderma	0.000569	0.000569	CcSEcCtD
Paricalcitol—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000568	0.000568	CcSEcCtD
Paricalcitol—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000567	0.000567	CcSEcCtD
Paricalcitol—Asthenia—Leflunomide—systemic scleroderma	0.000567	0.000567	CcSEcCtD
Paricalcitol—Feeling abnormal—Lisinopril—systemic scleroderma	0.000559	0.000559	CcSEcCtD
Paricalcitol—Pruritus—Leflunomide—systemic scleroderma	0.000559	0.000559	CcSEcCtD
Paricalcitol—Connective tissue disorder—Prednisone—systemic scleroderma	0.000558	0.000558	CcSEcCtD
Paricalcitol—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000556	0.000556	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000555	0.000555	CcSEcCtD
Paricalcitol—Dizziness—Azathioprine—systemic scleroderma	0.000553	0.000553	CcSEcCtD
Paricalcitol—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000551	0.000551	CcSEcCtD
Paricalcitol—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000546	0.000546	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000542	0.000542	CcSEcCtD
Paricalcitol—Asthenia—Mycophenolic acid—systemic scleroderma	0.000541	0.000541	CcSEcCtD
Paricalcitol—Diarrhoea—Leflunomide—systemic scleroderma	0.000541	0.000541	CcSEcCtD
Paricalcitol—Urticaria—Lisinopril—systemic scleroderma	0.000539	0.000539	CcSEcCtD
Paricalcitol—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000538	0.000538	CcSEcCtD
Paricalcitol—Abdominal pain—Lisinopril—systemic scleroderma	0.000537	0.000537	CcSEcCtD
Paricalcitol—Body temperature increased—Lisinopril—systemic scleroderma	0.000537	0.000537	CcSEcCtD
Paricalcitol—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000534	0.000534	CcSEcCtD
Paricalcitol—Pruritus—Mycophenolic acid—systemic scleroderma	0.000533	0.000533	CcSEcCtD
Paricalcitol—Vomiting—Azathioprine—systemic scleroderma	0.000532	0.000532	CcSEcCtD
Paricalcitol—Pneumonia—Methotrexate—systemic scleroderma	0.000531	0.000531	CcSEcCtD
Paricalcitol—Eye disorder—Prednisone—systemic scleroderma	0.00053	0.00053	CcSEcCtD
Paricalcitol—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00053	0.00053	CcSEcCtD
Paricalcitol—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000529	0.000529	CcSEcCtD
Paricalcitol—Infestation NOS—Methotrexate—systemic scleroderma	0.000528	0.000528	CcSEcCtD
Paricalcitol—Infestation—Methotrexate—systemic scleroderma	0.000528	0.000528	CcSEcCtD
Paricalcitol—Rash—Azathioprine—systemic scleroderma	0.000528	0.000528	CcSEcCtD
Paricalcitol—Dermatitis—Azathioprine—systemic scleroderma	0.000527	0.000527	CcSEcCtD
Paricalcitol—Depression—Methotrexate—systemic scleroderma	0.000527	0.000527	CcSEcCtD
Paricalcitol—Headache—Azathioprine—systemic scleroderma	0.000524	0.000524	CcSEcCtD
Paricalcitol—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000524	0.000524	CcSEcCtD
Paricalcitol—Dizziness—Leflunomide—systemic scleroderma	0.000523	0.000523	CcSEcCtD
Paricalcitol—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000517	0.000517	CcSEcCtD
Paricalcitol—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000516	0.000516	CcSEcCtD
Paricalcitol—Angiopathy—Prednisone—systemic scleroderma	0.000515	0.000515	CcSEcCtD
Paricalcitol—Conjunctivitis—Methotrexate—systemic scleroderma	0.000514	0.000514	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000514	0.000514	CcSEcCtD
Paricalcitol—Immune system disorder—Prednisone—systemic scleroderma	0.000513	0.000513	CcSEcCtD
Paricalcitol—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000509	0.000509	CcSEcCtD
Paricalcitol—Pain—Mycophenolate mofetil—systemic scleroderma	0.000509	0.000509	CcSEcCtD
Paricalcitol—Arrhythmia—Prednisone—systemic scleroderma	0.000507	0.000507	CcSEcCtD
Paricalcitol—Sweating—Methotrexate—systemic scleroderma	0.000507	0.000507	CcSEcCtD
Paricalcitol—Vomiting—Leflunomide—systemic scleroderma	0.000502	0.000502	CcSEcCtD
Paricalcitol—Alopecia—Prednisone—systemic scleroderma	0.000502	0.000502	CcSEcCtD
Paricalcitol—Hypersensitivity—Lisinopril—systemic scleroderma	0.0005	0.0005	CcSEcCtD
Paricalcitol—Dizziness—Mycophenolic acid—systemic scleroderma	0.000498	0.000498	CcSEcCtD
Paricalcitol—Epistaxis—Methotrexate—systemic scleroderma	0.000498	0.000498	CcSEcCtD
Paricalcitol—Rash—Leflunomide—systemic scleroderma	0.000498	0.000498	CcSEcCtD
Paricalcitol—Dermatitis—Leflunomide—systemic scleroderma	0.000498	0.000498	CcSEcCtD
Paricalcitol—Mental disorder—Prednisone—systemic scleroderma	0.000497	0.000497	CcSEcCtD
Paricalcitol—Nausea—Azathioprine—systemic scleroderma	0.000497	0.000497	CcSEcCtD
Paricalcitol—Headache—Leflunomide—systemic scleroderma	0.000495	0.000495	CcSEcCtD
Paricalcitol—Malnutrition—Prednisone—systemic scleroderma	0.000494	0.000494	CcSEcCtD
Paricalcitol—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00049	0.00049	CcSEcCtD
Paricalcitol—Asthenia—Lisinopril—systemic scleroderma	0.000487	0.000487	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000486	0.000486	CcSEcCtD
Paricalcitol—Pruritus—Lisinopril—systemic scleroderma	0.00048	0.00048	CcSEcCtD
Paricalcitol—Vomiting—Mycophenolic acid—systemic scleroderma	0.000479	0.000479	CcSEcCtD
Paricalcitol—Rash—Mycophenolic acid—systemic scleroderma	0.000475	0.000475	CcSEcCtD
Paricalcitol—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000475	0.000475	CcSEcCtD
Paricalcitol—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000473	0.000473	CcSEcCtD
Paricalcitol—Headache—Mycophenolic acid—systemic scleroderma	0.000472	0.000472	CcSEcCtD
Paricalcitol—Pharyngitis—Methotrexate—systemic scleroderma	0.000471	0.000471	CcSEcCtD
Paricalcitol—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00047	0.00047	CcSEcCtD
Paricalcitol—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00047	0.00047	CcSEcCtD
Paricalcitol—Nausea—Leflunomide—systemic scleroderma	0.000469	0.000469	CcSEcCtD
Paricalcitol—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000468	0.000468	CcSEcCtD
Paricalcitol—Urethral disorder—Methotrexate—systemic scleroderma	0.000465	0.000465	CcSEcCtD
Paricalcitol—Diarrhoea—Lisinopril—systemic scleroderma	0.000465	0.000465	CcSEcCtD
Paricalcitol—Ill-defined disorder—Prednisone—systemic scleroderma	0.000458	0.000458	CcSEcCtD
Paricalcitol—Anaemia—Prednisone—systemic scleroderma	0.000457	0.000457	CcSEcCtD
Paricalcitol—Agitation—Prednisone—systemic scleroderma	0.000454	0.000454	CcSEcCtD
Paricalcitol—Angioedema—Prednisone—systemic scleroderma	0.000451	0.000451	CcSEcCtD
Paricalcitol—Dizziness—Lisinopril—systemic scleroderma	0.000449	0.000449	CcSEcCtD
Paricalcitol—Nausea—Mycophenolic acid—systemic scleroderma	0.000448	0.000448	CcSEcCtD
Paricalcitol—Malaise—Prednisone—systemic scleroderma	0.000446	0.000446	CcSEcCtD
Paricalcitol—Vertigo—Prednisone—systemic scleroderma	0.000444	0.000444	CcSEcCtD
Paricalcitol—Eye disorder—Methotrexate—systemic scleroderma	0.000443	0.000443	CcSEcCtD
Paricalcitol—Syncope—Prednisone—systemic scleroderma	0.000443	0.000443	CcSEcCtD
Paricalcitol—Cardiac disorder—Methotrexate—systemic scleroderma	0.00044	0.00044	CcSEcCtD
Paricalcitol—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000438	0.000438	CcSEcCtD
Paricalcitol—Loss of consciousness—Prednisone—systemic scleroderma	0.000434	0.000434	CcSEcCtD
Paricalcitol—Vomiting—Lisinopril—systemic scleroderma	0.000432	0.000432	CcSEcCtD
Paricalcitol—Angiopathy—Methotrexate—systemic scleroderma	0.00043	0.00043	CcSEcCtD
Paricalcitol—Immune system disorder—Methotrexate—systemic scleroderma	0.000428	0.000428	CcSEcCtD
Paricalcitol—Rash—Lisinopril—systemic scleroderma	0.000428	0.000428	CcSEcCtD
Paricalcitol—Dermatitis—Lisinopril—systemic scleroderma	0.000428	0.000428	CcSEcCtD
Paricalcitol—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000427	0.000427	CcSEcCtD
Paricalcitol—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000427	0.000427	CcSEcCtD
Paricalcitol—Hypertension—Prednisone—systemic scleroderma	0.000427	0.000427	CcSEcCtD
Paricalcitol—Chills—Methotrexate—systemic scleroderma	0.000426	0.000426	CcSEcCtD
Paricalcitol—Headache—Lisinopril—systemic scleroderma	0.000425	0.000425	CcSEcCtD
Paricalcitol—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000421	0.000421	CcSEcCtD
Paricalcitol—Arthralgia—Prednisone—systemic scleroderma	0.000421	0.000421	CcSEcCtD
Paricalcitol—Myalgia—Prednisone—systemic scleroderma	0.000421	0.000421	CcSEcCtD
Paricalcitol—Anxiety—Prednisone—systemic scleroderma	0.000419	0.000419	CcSEcCtD
Paricalcitol—Alopecia—Methotrexate—systemic scleroderma	0.000419	0.000419	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000418	0.000418	CcSEcCtD
Paricalcitol—Discomfort—Prednisone—systemic scleroderma	0.000416	0.000416	CcSEcCtD
Paricalcitol—Mental disorder—Methotrexate—systemic scleroderma	0.000416	0.000416	CcSEcCtD
Paricalcitol—Malnutrition—Methotrexate—systemic scleroderma	0.000413	0.000413	CcSEcCtD
Paricalcitol—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000407	0.000407	CcSEcCtD
Paricalcitol—Dysgeusia—Methotrexate—systemic scleroderma	0.000404	0.000404	CcSEcCtD
Paricalcitol—Nausea—Lisinopril—systemic scleroderma	0.000403	0.000403	CcSEcCtD
Paricalcitol—Oedema—Prednisone—systemic scleroderma	0.000403	0.000403	CcSEcCtD
Paricalcitol—Infection—Prednisone—systemic scleroderma	0.000401	0.000401	CcSEcCtD
Paricalcitol—Back pain—Methotrexate—systemic scleroderma	0.000399	0.000399	CcSEcCtD
Paricalcitol—Shock—Prednisone—systemic scleroderma	0.000397	0.000397	CcSEcCtD
Paricalcitol—Nervous system disorder—Prednisone—systemic scleroderma	0.000395	0.000395	CcSEcCtD
Paricalcitol—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000393	0.000393	CcSEcCtD
Paricalcitol—Skin disorder—Prednisone—systemic scleroderma	0.000392	0.000392	CcSEcCtD
Paricalcitol—Hyperhidrosis—Prednisone—systemic scleroderma	0.00039	0.00039	CcSEcCtD
Paricalcitol—Anorexia—Prednisone—systemic scleroderma	0.000384	0.000384	CcSEcCtD
Paricalcitol—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000383	0.000383	CcSEcCtD
Paricalcitol—Anaemia—Methotrexate—systemic scleroderma	0.000382	0.000382	CcSEcCtD
Paricalcitol—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000378	0.000378	CcSEcCtD
Paricalcitol—Rash—Mycophenolate mofetil—systemic scleroderma	0.000375	0.000375	CcSEcCtD
Paricalcitol—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000375	0.000375	CcSEcCtD
Paricalcitol—Headache—Mycophenolate mofetil—systemic scleroderma	0.000373	0.000373	CcSEcCtD
Paricalcitol—Malaise—Methotrexate—systemic scleroderma	0.000372	0.000372	CcSEcCtD
Paricalcitol—Vertigo—Methotrexate—systemic scleroderma	0.000371	0.000371	CcSEcCtD
Paricalcitol—Leukopenia—Methotrexate—systemic scleroderma	0.00037	0.00037	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000367	0.000367	CcSEcCtD
Paricalcitol—Insomnia—Prednisone—systemic scleroderma	0.000365	0.000365	CcSEcCtD
Paricalcitol—Paraesthesia—Prednisone—systemic scleroderma	0.000362	0.000362	CcSEcCtD
Paricalcitol—Cough—Methotrexate—systemic scleroderma	0.00036	0.00036	CcSEcCtD
Paricalcitol—Dyspepsia—Prednisone—systemic scleroderma	0.000355	0.000355	CcSEcCtD
Paricalcitol—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000353	0.000353	CcSEcCtD
Paricalcitol—Chest pain—Methotrexate—systemic scleroderma	0.000352	0.000352	CcSEcCtD
Paricalcitol—Arthralgia—Methotrexate—systemic scleroderma	0.000352	0.000352	CcSEcCtD
Paricalcitol—Myalgia—Methotrexate—systemic scleroderma	0.000352	0.000352	CcSEcCtD
Paricalcitol—Decreased appetite—Prednisone—systemic scleroderma	0.000351	0.000351	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000349	0.000349	CcSEcCtD
Paricalcitol—Fatigue—Prednisone—systemic scleroderma	0.000348	0.000348	CcSEcCtD
Paricalcitol—Discomfort—Methotrexate—systemic scleroderma	0.000347	0.000347	CcSEcCtD
Paricalcitol—Constipation—Prednisone—systemic scleroderma	0.000345	0.000345	CcSEcCtD
Paricalcitol—Confusional state—Methotrexate—systemic scleroderma	0.00034	0.00034	CcSEcCtD
Paricalcitol—Infection—Methotrexate—systemic scleroderma	0.000335	0.000335	CcSEcCtD
Paricalcitol—Feeling abnormal—Prednisone—systemic scleroderma	0.000332	0.000332	CcSEcCtD
Paricalcitol—Nervous system disorder—Methotrexate—systemic scleroderma	0.00033	0.00033	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Prednisone—systemic scleroderma	0.00033	0.00033	CcSEcCtD
Paricalcitol—Skin disorder—Methotrexate—systemic scleroderma	0.000327	0.000327	CcSEcCtD
Paricalcitol—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000326	0.000326	CcSEcCtD
Paricalcitol—Anorexia—Methotrexate—systemic scleroderma	0.000321	0.000321	CcSEcCtD
Paricalcitol—Urticaria—Prednisone—systemic scleroderma	0.00032	0.00032	CcSEcCtD
Paricalcitol—Body temperature increased—Prednisone—systemic scleroderma	0.000319	0.000319	CcSEcCtD
Paricalcitol—Abdominal pain—Prednisone—systemic scleroderma	0.000319	0.000319	CcSEcCtD
Paricalcitol—Hypotension—Methotrexate—systemic scleroderma	0.000315	0.000315	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000307	0.000307	CcSEcCtD
Paricalcitol—Insomnia—Methotrexate—systemic scleroderma	0.000305	0.000305	CcSEcCtD
Paricalcitol—Paraesthesia—Methotrexate—systemic scleroderma	0.000303	0.000303	CcSEcCtD
Paricalcitol—Dyspnoea—Methotrexate—systemic scleroderma	0.0003	0.0003	CcSEcCtD
Paricalcitol—Somnolence—Methotrexate—systemic scleroderma	0.0003	0.0003	CcSEcCtD
Paricalcitol—Hypersensitivity—Prednisone—systemic scleroderma	0.000297	0.000297	CcSEcCtD
Paricalcitol—Dyspepsia—Methotrexate—systemic scleroderma	0.000297	0.000297	CcSEcCtD
Paricalcitol—Decreased appetite—Methotrexate—systemic scleroderma	0.000293	0.000293	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000291	0.000291	CcSEcCtD
Paricalcitol—Fatigue—Methotrexate—systemic scleroderma	0.000291	0.000291	CcSEcCtD
Paricalcitol—Asthenia—Prednisone—systemic scleroderma	0.000289	0.000289	CcSEcCtD
Paricalcitol—Pain—Methotrexate—systemic scleroderma	0.000288	0.000288	CcSEcCtD
Paricalcitol—Pruritus—Prednisone—systemic scleroderma	0.000285	0.000285	CcSEcCtD
Paricalcitol—Feeling abnormal—Methotrexate—systemic scleroderma	0.000278	0.000278	CcSEcCtD
Paricalcitol—Diarrhoea—Prednisone—systemic scleroderma	0.000276	0.000276	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000276	0.000276	CcSEcCtD
Paricalcitol—Urticaria—Methotrexate—systemic scleroderma	0.000268	0.000268	CcSEcCtD
Paricalcitol—Dizziness—Prednisone—systemic scleroderma	0.000267	0.000267	CcSEcCtD
Paricalcitol—Abdominal pain—Methotrexate—systemic scleroderma	0.000266	0.000266	CcSEcCtD
Paricalcitol—Body temperature increased—Methotrexate—systemic scleroderma	0.000266	0.000266	CcSEcCtD
Paricalcitol—Vomiting—Prednisone—systemic scleroderma	0.000256	0.000256	CcSEcCtD
Paricalcitol—Rash—Prednisone—systemic scleroderma	0.000254	0.000254	CcSEcCtD
Paricalcitol—Dermatitis—Prednisone—systemic scleroderma	0.000254	0.000254	CcSEcCtD
Paricalcitol—Headache—Prednisone—systemic scleroderma	0.000253	0.000253	CcSEcCtD
Paricalcitol—Hypersensitivity—Methotrexate—systemic scleroderma	0.000248	0.000248	CcSEcCtD
Paricalcitol—Asthenia—Methotrexate—systemic scleroderma	0.000242	0.000242	CcSEcCtD
Paricalcitol—Nausea—Prednisone—systemic scleroderma	0.00024	0.00024	CcSEcCtD
Paricalcitol—Pruritus—Methotrexate—systemic scleroderma	0.000238	0.000238	CcSEcCtD
Paricalcitol—Diarrhoea—Methotrexate—systemic scleroderma	0.000231	0.000231	CcSEcCtD
Paricalcitol—Dizziness—Methotrexate—systemic scleroderma	0.000223	0.000223	CcSEcCtD
Paricalcitol—Vomiting—Methotrexate—systemic scleroderma	0.000214	0.000214	CcSEcCtD
Paricalcitol—Rash—Methotrexate—systemic scleroderma	0.000212	0.000212	CcSEcCtD
Paricalcitol—Dermatitis—Methotrexate—systemic scleroderma	0.000212	0.000212	CcSEcCtD
Paricalcitol—Headache—Methotrexate—systemic scleroderma	0.000211	0.000211	CcSEcCtD
Paricalcitol—Nausea—Methotrexate—systemic scleroderma	0.0002	0.0002	CcSEcCtD
